Natali Shiron,Ayelet Shai
Natali Shiron
Impact of axillary disease extent defined by baseline 18F-FDG PET/CT on the accuracy of axillary surgical staging after neoadjuvant systemic therapy in clinically node-positive breast cancer [0.03%]
基线18F-FDG PET/CT定义的腋窝病灶范围对新辅助系统治疗后临床阳性淋巴结乳腺癌腋窝分期准确度的影响
Cornelis M de Mooij,Janine M Simons,Florien J G van Amstel et al.
Cornelis M de Mooij et al.
Background: In clinically node-positive patients, sentinel lymph node biopsy (SLNB), marking axillary lymph node with radioactive iodine seed (MARI), and combined SLNB/MARI (RISAS-procedure) can replace axillary lymph nod...
Association between body mass index and risk of breast cancer according to breast cancer subtypes: A systematic review and meta-analysis [0.03%]
基于乳腺癌亚型的体质指数与乳腺癌风险关联的系统评价和Meta分析
Chiara Dauccia,Marco Bruzzone,Luca Arecco et al.
Chiara Dauccia et al.
Background: Higher body mass index (BMI) is a risk factor for breast cancer (BC) development, but the relationship with BC subtypes in pre- and post-menopausal women remains unclear. ...
Epigenetic and fragment-based profiling across CDK4/6 inhibitors in first-line HR+/HER2- metastatic breast cancer. An ancillary analysis of the MAGNETIC.1 study [0.03%]
CDK4/6抑制剂在HR+/HER2-一线晚期乳腺癌中的表观遗传学及片段化谱型分析：MAGNETIC.1研究的探索性分析
Claudia Noto,Lorenzo Foffano,Fabiola Giudici et al.
Claudia Noto et al.
Background: CDK4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) represent the standard of care for hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) patients. However, ...
Letter to the Editor "Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor-positive, HER2-positive breast cancer" [0.03%]
致编辑的信：“激素受体阳性、HER2阳性乳腺癌前绝经期患者的辅助性卵巢功能抑制和芳香化酶抑制剂”
Akshat Verma,Dileep Ramesh Hoysal,Amar Deshpande et al.
Akshat Verma et al.
Pleomorphic and florid lobular carcinoma in situ of the Breast: A systematic review of current evidence and knowledge gaps [0.03%]
乳腺多形性和 florid 小叶原位癌的系统性回顾：现有证据及知识空白分析
Massimo Ferrucci,Daniele Passeri,Francesco Milardi et al.
Massimo Ferrucci et al.
Introduction: Pleomorphic (PLCIS) and florid (FLCIS) lobular carcinoma in situ are uncommon entities, characterized by significant architectural distortion and cellular atypia. Their rarity poses three key clinical challe...
Breast cancer risk in women with neurofibromatosis type 1: a register-based cohort study from Denmark and Sweden [0.03%]
I型神经纤维瘤病女性患者乳腺癌风险的注册登记队列研究（来自丹麦和瑞典）
Giorgio Tettamanti,Annie Pedersen,Maria Feychting et al.
Giorgio Tettamanti et al.
Background: An increased risk of breast cancer has been reported in women with neurofibromatosis type 1 (NF1), especially at younger ages, and NF1-related breast cancer has been associated with poor survival. We performed...
Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approach [0.03%]
预测激素受体阳性（HR+/HER2-）转移性乳腺癌（MBC）接受CDK4/6抑制剂治疗的无进展生存期：一种机器学习方法
Sergio Pannunzio,Luca Mastrantoni,Noemi Maliziola et al.
Sergio Pannunzio et al.
Background: In HR+/HER2- metastatic breast cancer (MBC), CDK4/6 inhibitors combined with endocrine therapy (ET) significantly improve progression-free survival (PFS). Machine learning (ML) approaches may improve individua...
Large-scale DNA organization analysis of primary breast cancers for prediction of axillary lymph node metastases [0.03%]
原发性乳腺癌的大规模DNA组织分析以预测腋窝淋巴结转移
Nikolay Alabi,Alan Nichol,Fumiya Inaba et al.
Nikolay Alabi et al.
Breast cancer is the leading cause of cancer-related deaths among women worldwide. It is standard practice for patients to undergo a sentinel lymph node biopsy (SLNB) with breast surgery for staging. However, more than 60% of patients with ...
Identifying premenopausal patients with early-stage hormone receptor-positive breast cancer at minimal risk of distant recurrence by breast cancer index [0.03%]
利用乳腺癌指数识别出极低远处复发风险的早期激素受体阳性乳腺癌绝经前患者
Ruth M O&#x;Regan,Yue Ren,Yi Zhang et al.
Ruth M O&#x;Regan et al.
Background: An adjusted Breast Cancer Index (BCI) model with an additional cutpoint identified postmenopausal women with hormone-receptor-positive node-negative disease at minimal (